Schinkel Arend F L, Poldermans Don, Rizzello Vittoria, van Domburg Ron T, Valkema Roelf, Elhendy Abdou, Biagini Elena, Krenning Eric P, Simoons Maarten L, Bax Jeroen J
Thoraxcenter, Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
J Nucl Med. 2006 Jan;47(1):68-73.
Nuclear imaging using (18)F-FDG is an established method for the noninvasive assessment of myocardial viability. Data on the value of (18)F-FDG imaging in patients with diabetes mellitus are scarce. The aim of this study was to assess whether, in patients with diabetes mellitus and ischemic left ventricular (LV) dysfunction, (18)F-FDG imaging can predict improvement of LV function and heart failure symptoms after coronary revascularization.
A total of 130 consecutive patients with ischemic LV dysfunction who were already scheduled for surgical revascularization were studied; 34 of the patients had diabetes mellitus. All patients underwent radionuclide ventriculography to assess left ventricular ejection fraction (LVEF), resting 2-dimensional echocardiography to identify dysfunctional myocardial tissue, and dual-isotope (18)F-FDG/(99m)Tc-tetrofosmin SPECT after oral administration of acipimox. Nine to 12 mo after coronary revascularization, radionuclide ventriculography and echocardiography were repeated. An improvement in LVEF by at least 5% was considered significant.
(18)F-FDG SPECT demonstrated that 610 (50%) of 1,212 dysfunctional segments were viable. Patients with and without diabetes mellitus had a comparable number of dysfunctional but viable segments per patient. Also, the number of patients with a substantial amount of dysfunctional but viable myocardium (>or=4 viable segments) was comparable between the groups with and without diabetes mellitus. The presence of substantial viability on (18)F-FDG SPECT was predictive of improvement in LVEF and heart failure symptoms postoperatively (sensitivity and specificity of 82% and 89%, respectively, in patients with diabetes and 83% and 93%, respectively, in patients without diabetes; not statistically significant).
(18)F-FDG SPECT is practical for routine assessment of myocardial viability in patients with ischemic LV dysfunction with or without diabetes mellitus. Patients with substantial myocardial viability on (18)F-FDG SPECT have a high probability of improvement of LV function and symptoms after coronary revascularization, irrespective of the absence or presence of diabetes mellitus.
使用(18)F-FDG的核成像技术是一种用于无创评估心肌活力的既定方法。关于(18)F-FDG成像在糖尿病患者中的价值的数据很少。本研究的目的是评估在患有糖尿病和缺血性左心室(LV)功能障碍的患者中,(18)F-FDG成像是否能够预测冠状动脉血运重建术后左心室功能和心力衰竭症状的改善情况。
共研究了130例已计划接受手术血运重建的连续性缺血性左心室功能障碍患者;其中34例患者患有糖尿病。所有患者均接受放射性核素心室造影以评估左心室射血分数(LVEF),静息二维超声心动图以识别功能失调的心肌组织,并在口服阿昔莫司后进行双同位素(18)F-FDG/(99m)Tc-替曲膦单光子发射计算机断层扫描(SPECT)。冠状动脉血运重建术后9至12个月,重复进行放射性核素心室造影和超声心动图检查。LVEF至少提高5%被认为具有显著性。
(18)F-FDG SPECT显示,1212个功能失调节段中有610个(50%)存活。有糖尿病和无糖尿病的患者每位患者功能失调但存活的节段数量相当。此外,有大量功能失调但存活心肌(≥4个存活节段)的患者数量在有糖尿病和无糖尿病组之间也相当。(18)F-FDG SPECT上存在大量存活心肌可预测术后LVEF和心力衰竭症状的改善(糖尿病患者的敏感性和特异性分别为82%和89%,无糖尿病患者分别为83%和93%;无统计学显著性)。
(18)F-FDG SPECT对于有或无糖尿病的缺血性左心室功能障碍患者的心肌活力常规评估是实用的。无论有无糖尿病,(18)F-FDG SPECT上有大量心肌存活的患者在冠状动脉血运重建术后左心室功能和症状改善的可能性很高。